促进结肠镜筛查依从性与序贯粪便潜血试验随机对照试验
这项随机对照试验在3个不同临床中心纳入40-69岁参与者,比较单次筛查结肠镜与序贯高敏粪便潜血试验(HSgFOBT)的依从性及病理检出。结肠镜组首轮依从性83.6%,高于HSgFOBT组73.1%(RR 1.14),但HSgFOBT组4轮序贯依从性仅38.3%。结肠镜组晚期肿瘤或大锯齿状病变检出率8.2%,高于序贯依从者的3.3%和非序贯依从者的0.6%。
要点
- 结肠镜组首轮依从性83.6%,HSgFOBT组73.1%(RR 1.14)。
- HSgFOBT组4轮序贯依从性仅38.3%,结肠镜组为83.6%。
- 非序贯依从者晚期肿瘤或大锯齿状病变检出率0.6%,低于序贯依从者的3.3%。
核心结论
- 序贯HSgFOBT轮次的观察依从性低于单次筛查结肠镜。
- 非序贯HSgFOBT依从性相比序贯依从性,晚期肿瘤或大锯齿状病变检出较差。
- 交叉到结肠镜并选择接受结肠镜者中检出的晚期肿瘤或大锯齿状病变数量最多。
- 若允许交叉到筛查结肠镜,HSgFOBT筛查项目的效果可能增强。
研究设计与样本
- 随机临床试验,在3个代表不同临床设置的中心纳入40-69岁参与者。
- 参与者随机分为单次筛查结肠镜组与由4-7轮组成的序贯HSgFOBT组。
- 共3523名参与者纳入试验,结肠镜组1761名,HSgFOBT组1762名。
- 测量指标包括筛查结肠镜初始依从性、HSgFOBT序贯依从性、HSgFOBT阳性后随访结肠镜、交叉到结肠镜及晚期肿瘤或大锯齿状病变检出。
主要发现
- 1轮后依从性:结肠镜组1473名(83.6%)vs HSgFOBT组1288名(73.1%),RR 1.14(95%CI 1.10-1.19),P≤.001。
- 4轮序贯HSgFOBT依从性仅674名(38.3%),RR 2.19(95%CI 2.05-2.33)。
- 整个研究期间任何筛查总体依从性:结肠镜组1558名(88.5%)vs HSgFOBT组1493名(84.7%),RR 1.04(95%CI 1.02-1.07)。
- 前4轮中436名参与者(24.7%)交叉到筛查结肠镜。
- 研究前12个月按方案依从的结肠镜组1473名中121名(8.2%)检出ADN-SERs;非序贯依从HSgFOBT者(n=709)检出0.6%,相比序贯依从者(n=647)的3.3%,RR 2.52(95%CI 1.61-3.98);非序贯依从者相比序贯依从者RR 14.72(95%CI 5.46-39.67)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Colorectal cancer (CRC) screening guidelines include screening colonoscopy and sequential high-sensitivity fecal occult blood testing (HSgFOBT), with expectation of similar effectiveness based on the assumption of similar high adherence. However, adherence to screening colonoscopy compared with sequential HSgFOBT has not been reported. In this randomized clinical trial, we assessed adherence and pathology findings for a single screening colonoscopy vs sequential and nonsequential HSgFOBTs. METHODS: Participants aged 40-69 years were enrolled at 3 centers representing different clinical settings. Participants were randomized into a single screening colonoscopy arm vs sequential HSgFOBT arm composed of 4-7 rounds. Initial adherence to screening colonoscopy and sequential adherence to HSgFOBT, follow-up colonoscopy for positive HSgFOBT tests, crossover to colonoscopy, and detection of advanced neoplasia or large serrated lesions (ADN-SERs) were measured. RESULTS: There were 3523 participants included in the trial; 1761 and 1762 participants were randomized to the screening colonoscopy and HSgFOBT arms, respectively. Adherence was 1473 (83.6%) for the screening colonoscopy arm vs 1288 (73.1%) for the HSgFOBT arm after 1 round (relative risk [RR], 1.14; 95% CI, 1.10-1.19; P ≤ .001), but only 674 (38.3%) over 4 sequential HSgFOBT rounds (RR, 2.19; 95% CI, 2.05-2.33). Overall adherence to any screening increased to 1558 (88.5%) in the screening colonoscopy arm during the entire study period and 1493 (84.7%) in the HSgFOBT arm (RR, 1.04; 95% CI, 1.02-1.07). Four hundred thirty-six participants (24.7%) crossed over to screening colonoscopy during the first 4 rounds. ADN-SERs were detected in 121 of the 1473 participants (8.2%) in the colonoscopy arm who were adherent to protocol in the first 12 months of the study, whereas detection of ADN-SERs among those who were not sequentially adherent (n = 709) to HSgFOBT was subpar (0.6%) (RR, 14.72; 95% CI, 5.46-39.67) compared with those who were sequentially adherent (3.3%) (n = 647) (RR, 2.52; 95% CI, 1.61-3.98) to HSgFOBT in the first 4 rounds. When including colonoscopies from HSgFOBT patients who were never positive yet crossed over (n = 1483), 5.5% of ADN-SERs were detected (RR, 1.50; 95% CI, 1.15-1.96) in the first 4 rounds. CONCLUSIONS: Observed adherence to sequential rounds of HSgFOBT was suboptimal compared with a single screening colonoscopy. Detection of ADN-SERs was inferior when nonsequential HSgFOBT adherence was compared with sequential adherence. However, the greatest number of ADN-SERs was detected among those who crossed over to colonoscopy and opted to receive a colonoscopy. The effectiveness of an HSgFOBT screening program may be enhanced if crossover to screening colonoscopy is permitted. CLINICALTRIALS: gov, Number: NCT00102011.
引用
- Zauber AG, Winawer SJ, O'Brien MJ, et al. Randomized Trial of Facilitated Adherence to Screening Colonoscopy vs Sequential Fecal-Based Blood Test. Gastroenterology. 2023. PMID: 36948424. doi:10.1053/j.gastro.2023.03.206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。